cerivastatin

Known as: cerivastatin [Chemical/Ingredient] 
A synthetic lipid-lowering agent. Cerivastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which… (More)
National Institutes of Health

Related topics

Related topics

13 relations
Cerivastatin sodiumCoronary Artery DiseaseDrug AllergyGemfibrozil
(More)

Narrower (2)

CertaKazak

Broader (2)

Hydroxymethylglutaryl-CoA Reductase InhibitorsPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the…
A serious pharmacokinetic interaction between cerivastatin (CER) and gemfibrozil (GEM) has been reported. In the present study… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.
The mechanism involved in the clinically relevant drug-drug interaction (DDI) between cerivastatin (CER) and cyclosporin A (CsA… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
BACKGROUND Concomitant use of gemfibrozil with statins, particularly with cerivastatin, increases the risk of rhabdomyolysis, but… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin.
BACKGROUND Although statins preserve endothelial function by reducing serum cholesterol levels, it has been suggested they may… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 5
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.
We previously have found that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Withdrawal of cerivastatin from the world market
Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.
BACKGROUND Unstable atherosclerotic plaques that cause acute coronary events usually contain abundant macrophages expressing… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.
BACKGROUND Long-term therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) has been shown to reduce levels… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.
Cerivastatin is used in the treatment of hypercholesterolemia to inhibit 3-hydroxy 3-methylglutaryl coenzyme A reductase and thus… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis.
Development of severe sepsis is thought to result from the overproduction of cytokines, such as tumor necrosis factor-alpha (TNF… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?